ENTECAVIR / 0,5 mg; 1 mg Tablet

Adrenergics (B2 agonists) in combination with corticosteroids - Asthma & COPD

Thyroid Preparations - Hypothyroidism

Antiepileptic

NSAID

PDE5 Inhibitors - Erectile dysfunction

Selective serotonin reuptake inhibitors - Antidepressants

Nucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B

Parkinson

Anticholinergics & anti-floating agents (combi)- Functional gastrointestinal disorders

Antihistaminics & Leukotriene receptor antagonists (combi)- Rhinitis & Asthma

Selective beta blocking agents- Hypertension

Anticholinesterases - Dementia & Alzheimer

Abdi İbrahim has been awarded the 'Equal Opportunity Model' (FEM) certificate, developed by KAGIDER with the technical support of the World Bank, to promote gender equality in business life and enhance women's productivity. Deniz Daver, President of Human and Culture Group, expressed their happiness in receiving this certificate, stating, “This certificate, which acknowledges companies' sensitive approaches to gender equality and women's empowerment in employment, is an important indicator reflecting Abdi İbrahim's vision of inclusiveness. We see FEM certificate as a reward for our determined and continuous efforts in this field.

Turkish pharmaceutical industry leader Abdi Ibrahim s journey began in 1912.In addition to its partnerships with more than 30 licensing firms across the globe, Abdi Ibrahim develops its own products with 250 brands and 500 products.Abdi Ibrahim has subsidiaries operating in 17 countries outside Turkey, exports to more than 70 countries from the European Union to Canada, North Africa to Asia and generates the highest employment rate in the Turkish pharmaceutical industry with 5500 qualified employees.

Abdi İbrahim, the uninterrupted leader of the Turkish pharmaceutical industry for 21 years, received awards in 5 categories at the Crystal Mortar Awards organized by the Chemists' Association.

 Acting for 111 years with the mission of improving life, Abdi İbrahim received awards in 5 categories at the Crystal Mortar Awards, given within the scope of the 11th International Pharmaceutical Chemistry Congress for its R&D studies and investments. On the opening day of the 11th International Pharmaceutical Chemistry Congress organized by the Chemists' Association in Antalya this year, the R&D activities of pharmaceutical companies were awarded in 7 categories. Abdi İbrahim won awards in 5 categories, including the “Pharmaceutical Company with the Most R&D Investments” category.

Providing accommodation for children and their families who come to Istanbul for cancer treatment

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, has initiated a social project for children undergoing cancer treatment and their families. Abdi İbrahim Foundation House of Kindness, which provides accommodation for children who come to İstanbul for cancer treatment but face difficulties staying due to economic reasons, has opened its doors in Fatih, İstanbul. Speaking at the opening ceremony, Nesrin Barut Esirtgen, Deputy Chairperson of Abdi İbrahim and Chairperson of the Board of Trustees of the Abdi İbrahim Foundation, said: “Taking into account the accommodation needs of our children and their relatives who come to Istanbul for treatment, we realized the House of Kindness project to be part of the solution. We strongly believe that kindness and the passion for healing are contagious. Our House of Kindness is a reflection of this belief and will.” D...

The Sterile Inhalation Facility, jointly developed by Abdi İbrahim and GSK Türkiye in collaboration with the Investment Office of the Presidency of the Republic of Türkiye, commences operations.

The facility, built with an investment of TRY 340 million, will enable Türkiye to benefit from the advanced ‘nebule’ technology, which is used in the treatment of respiratory diseases. The facility is the first in the world capable of manufacturing the complete range of GSK’s nebule portfolio.

ANOTHER FIRST FROM ABDİ İBRAHİM

Abdi İbrahim, the leader in the Turkish pharmaceutical industry for 21 years, continues its unwavering commitment to investing in biotechnology. Abdi İbrahim has announced a technology transfer agreement with the Spanish biosimilar developer, mAbxience, which is among the world’s leading companies in the field.

Accordingly, a currently imported cancer drug will now be manufactured by AbdiBio. Nezih Barut, Chairman of Abdi İbrahim, noted the technology transfer’s significance as the first “cell-to-end product” biotech pharmaceutical in Türkiye.

ABDİ İBRAHİM STRIKES DEAL WITH ARONPHARMA

Abdi İbrahim, Türkiye's leading pharmaceutical company and a strong player in consumer health products, is collaborating with Aronpharma, a key European company specializing in innovative food supplements for their innovative brand Berroxin.

Abdi İbrahim has acquired sales and distribution rights in Türkiye for products that help support the immune system under the Berroxin brand of Aronpharma, which offers innovative food supplement products. The portfolio will be launched in the Turkish market starting in 2023 with the assurance of Abdi İbrahim.

The unrivalled leader in the Turkish pharmaceutical industry for 22 years, Abdi İbrahim attains a noteworthy achievement by earning a coveted spot on the Climate A list within the 2023 Carbon Disclosure Project (CDP) Climate Change Program. For 112 years marked by a passion for progress, Abdi İbrahim has actively embraced the green transformation by diligently integrating environmental considerations into its business models. Aligned with the ambitious 1.5°C target of the Paris Agreement, its greenhouse gas emission reduction targets boast the validation of the Science Based Targets Initiative (SBTi). Aligned with this target, the Company is resolutely aiming to curtail its Scope 1 and Scope 2 greenhouse gas emissions by 60 percent, and its Scope 3 emissions by 45 percent by 2030, measured against the baseline year 2020. 

Established in 2021 by Abdi İbrahim, the healing power of Türkiye, the Abdi İbrahim Foundation aims to impart swimming skills to children aged 5 to 8 with Down Syndrome through the social responsibility project, Brave Strokes. This initiative is realized in collaboration with the Down Syndrome Association of Türkiye.

Abdi İbrahim, the undisputed leader of the Turkish pharmaceutical industry for 22 years, has initiated a new project under the Abdi İbrahim Foundation, as part of its social investment programs that aim to create value for the country and society by healing the lives it touches.

Conducting its sustainability operations with the vision of “Healing the Future,” Abdi İbrahim has released its 6th Sustainability Report, covering the period of 2021-2022. The report includes Abdi İbrahim’s sustainability goals set for 2030, 2040, and 2050, within the framework of healing the future of the ecosystem, people and business, along with the projects carried out in line with these goals. Abdi İbrahim’s sustainability report offers a unique reading experience with digital artworks designed by artist Bager Akbay and his team, combining human imagination with artificial intelligence.

Planning its sustainability activities with a comprehensive perspective encompassing environmental, social, and governance aspects, Abdi İbrahim published its 6th Sustainability Report, detailing its sustainability efforts between January 1, 2021 and December 31, 2022. 

Abdi İbrahim forms a joint venture with Saudi Cigalah Healthcare, laying the foundation for expansion into Saudi Arabia and beyond, prioritizing exports as the initial step.

Abdi İbrahim extends its healing touch to the Gulf

Abdi İbrahim and CorPal unite to advance digital health

As the unrivaled leader of the Turkish pharmaceutical industry for 22 years, Abdi İbrahim seeks to maximize the advantages of digital health solutions for both patients and healthcare professionals through a comprehensive partnership with CorPal, an AI-supported holistic rehabilitation platform. Through this collaboration, patients requiring long-term follow-up can access mental and physical rehabilitation anytime and anywhere.

Abdi İbrahim, the healing power of Türkiye, has made a pioneering move in digital health through its collaboration with CorPal, an AI-supported holistic rehabilitation platform. Strengthening Abdi İbrahim's value-driven approach in the pharmaceutical industry and its technological leadership, this collaboration aims to develop innovative treatments, expand healthcare services, and provide solutions to help physicians improve patient care and monitoring.

Operating in the pharmaceutical industry for 109 years straight with the objective of healing life, Abdi İbrahim has become the main sponsor of H. Emre Sakcı, our record-breaking national swimmer who will be representing Turkey in the Tokyo Olympics. Having signed a 4-year sponsorship agreement with H. Emre Sakcı, our record-holding athlete in national and international breaststroke, Abdi İbrahim Chairman Nezih Barut said "As Turkey's national and leading pharmaceutical company, we have decided to support athletes who have the potential to earn medals for our country by competing in swimming, one of the Olympic sports branch, in international contests and especially the Olympics. We have signed a long-term sponsorship agreement with Emre Sakcı who has stood out with his steady success in swimming and we will be his main sponsor for 4 years, including the Paris 2024 Olympics. We will continue our support to ensure that more Turkish athletes participate in the Olympics and thus achieve more victories for our country in the area of sports." 

The unrivaled leader of the Turkish pharmaceutical industry for the last 19 years, Abdi İbrahim has once again broken new ground in the country's pharmaceutical industry by implementing a brand new social investment program that focuses on four main topics including "Health and Sports", "Social Innovation", "Raising Scientific Awareness in Youth" and "Volunteering Projects for Social Needs" with the aim of creating value in society by healing the lives we touch. In the framework of this program to be implemented as of 2021 with a long-term perspective, Abdi İbrahim has decided to support Emre Sakcı on his path to success with a four-year long-term sponsorship agreement in the scope of this program, the latter being one of the most important components of the company's sustainability strategy.

Emre Sakcı started swimming at the age of three and was selected to the A National Team at 15. He broke numerous records in national and international competitions throughout his career and is currently a licensed athlete of Fenerbahçe Sports Club. The sponsorship agreement with our record-breaking swimmer who will be representing Turkey in the 100-meters breaststroke category at the Tokyo Olympics that were postponed to July 2021 has been signed at Abdi İbrahim's headquarters in Maslak. 

Nezih Barut: "We are determined to give wing to our youth and to be by their side" 

Speaking about the sponsorship agreement, Abdi İbrahim Chairman Nezih Barut drew attention to the spirit of the era we are currently going through and stated "The pandemic has clearly proven that the biggest power of countries resides in the success stories they write at the international level. With every step we take, we take on the responsibility of glorifying our country brand. As Turkey, we need more success stories in every field, sports included."

Indicating that achievements in sports are some of the most efficient tools in contributing to a country's brand, Nezih Barut continued "The Olympics are the most powerful scene for countries to prove themselves. Being able to get on that stage and to compete there requires immense resolution and resilience. We are determined to stand by our young athletes who demonstrate that determination. As Abdi İbrahim, we take the first step with our national swimmer Emre Sakcı and plan on continuing with successful swimmers who pass the Olympics A threshold."

Affirming that Abdi İbrahim has been the unrivaled leader of the Turkish pharmaceutical industry for the last 19 years, Nezih Barut said "However, we never rest on our laurels. With the awareness that each and every success we achieve on the international scene will contribute to our country brand, we advance with discipline, resolution and determination on our path of becoming a global and sustainable company. As Abdi İbrahim, we develop social investment programs to show the young that they do have the capacity to change our country first, and then the world, and that they can look towards the future with hope, and we strive to provide them with various opportunities. Our greatest motivation in supporting dear Emre is the fact that he will be bearing our country's name and elevating our flag to the highest level in all lanes during the Olympics in Tokyo in 2021 and in Paris in 2024, and in World and European championships in the four years to come. We are proud to be supporting those who share our passion, courage and responsibility, especially young people who are the guarantors of the future. I am sure that starting from the Olympics to be held in July, we will all witness the fruits of Emre's resolute and disciplined labors. I wish that just like Emre, many more young Turkish athletes participate in the Olympics and that Emre becomes a strong role model and example, shining like a North Star with the successes he will achieve."

Expressing his delight in Abdi İbrahim -Turkey's leading pharmaceutical company, becoming his sponsor- Emre Sakcı stated "Abdi İbrahim's sponsorship support is an important source of motivation for young athletes like myself. I had the opportunity to get more acquainted with the company's vision since the managers of Abdi İbrahim contacted me. I noticed an incredible alignment between my personal sportive targets and those of Abdi İbrahim. This excited me a lot. I would like to thank them for instilling in me many significant values that are a part of the Olympics spirit and especially for supporting an athlete who has set himself goals in the international arena. The fact that their support extends to four years is an incredible source of confidence and motivation, and it brought with it a sense of responsibility as well. Now, with the support and opportunities that my main sponsor Abdi İbrahim will be giving me, my main goal is to give my best for my country in all competitions I will be participating in this year, particularly the Tokyo Olympics. I would like to extend my gratitude to first and foremost Nezih Barut and to all the Abdi İbrahim family who has been breaking new grounds for the last 109 years for believing in me and for sharing my path to success and my enthusiasm for achievement."

Who is Emre Sakcı? 

Our national swimmer Emre Sakcı was born on November the 15th 1997 in Izmir. He started swimming at age 3 and was selected to the A National Team at the age of 15, representing our country in the swimming branch. Sakcı has been an athlete of Fenerbahçe Sports Club since 2010 and has been training under Türker Oktay and Bahar Oktay. 

Emre Sakcı represented Turkey in the 2013 Utrecht European Youth Olympic Summer Festival, the 2015 Baku Islamic Solidarity Games and the 2018 Tarragona Mediterranean Games. He was the first Turkish athlete to break the world record in youth with a score of 26.67 during the selections for men's 50-meters breaststroke in the 2015 Turkey Inter-Club Short Lane Swimming Championship.

Ranking fifth in the world classification with a score of 25.89 in men's 50-meters breaststroke category during the World Short Lane Swimming Championship organized in China in 2018, our national swimmer won the silver medal in men's 50-meters breaststroke at the Europe Short Lane Swimming Championship held in 2019 in Scotland, thus winning the first medal in Turkish sports in this area.

Sakcı broke the European record and ranked first with a score of 25.50 in the 50-meters breaststroke branch in the International Swimming League organized in Budapest in 2020. Later on during the League, he once again broke his own European record and ranked first once more with a score of 25.29 in 50-meters breaststroke. His score made history by being the second fastest score in the world. He then went on to break another European record in the 100-meters breaststroke branch with a score 55.74 and broke 3 European records in the international swimming league.

Emre Sakcı will be representing our country in the 100-meters breaststroke during the Tokyo Olympics that have been postponed to July 2021 due to the global pandemic.

Centering all its business processes around sustainability with related actions and projects geared towards leaving a more livable world to future generations, Abdi İbrahim has achieved a significant international success. Abdi İbrahim has outperformed the global average in the Biotechnology & Pharmaceutical industry category in the Climate Change Program of the Carbon Disclosure Project (CDP), which is globally recognized as the strongest green NGO, and secured a place in the B- list.

Thanks to its efforts for achieving carbon neutrality by 2030 with a significant focus on sustainability and energy efficiency, Abdi İbrahim has achieved an important international success. With its first report to the Climate Change and Water Security Programs of the Carbon Disclosure Project, Abdi İbrahim scored higher than the global average in the Biotechnology Pharmaceutical industry category and qualified to be included in the B-list. Thus, the company achieved a significant success in the Carbon Disclosure Project, which is the world's largest environmental reporting platform including approximately 10,000 companies from around the globe.  

Commenting on Abdi İbrahim's success in being included in the B-list of the Carbon Disclosure Project, Abdi İbrahim Public Relations and Corporate Communications Director Dr. M. Oğuzcan Bülbül said, “At Abdi İbrahim, we strive to ensure a better, healthier and happier life for millions of people every day. As we continue our commercial operations and launch our investments, we always prioritize leaving a “good” mark on the society and the world we live in, planning all our actions with a particular focus on the environment. Although it was our first report to CDP, we are proud to have been included in the B-list in Climate Change and Water Security Programs. We are pleased to have achieved a score above the industry's global and European average in the field of climate change. Having applied and having been rated for the first time, we ranked above 85 out of 129 applicants in Turkey most of which have been engaged in such activities for more than 5-10 years. This important development has been a clear indication that Abdi İbrahim is on the right track with regards to its sustainability efforts. We have areas of development in both categories. Our ultimate goal is to be included in the list of companies with an 'A' rating. I am certain that we will achieve this with the cemented steps we will take.”

“We will continue to work for a better world and a better future”

Noting that these achievements will further consolidate Abdi İbrahim’s position in the area of sustainability, Bülbül also added: “The 2020 edition of the annual Global Risks Report by the World Economic Forum listed environmental risks as the top five of the global risks expected in the next decade. In today’s global landscape where we feel the impact of environmental risks more and more with each passing day, everyone, especially public and private organizations, has a crucial responsibility to fulfill. Companies that act with a strong sense of responsibility for the ecosystem, society and environment and take cemented steps towards a better future will be the agents of transformation in the future. At Abdi İbrahim, we have been driven by our mission to heal across all our operations for three generations; goodness is coded into our DNA. We strive to ensure a better and happier life for millions of people every day. This year, we transformed our ‘healing life’ mission into ‘healing the future’ and shaped our sustainability strategy around this concept. Empowered by our position as the healing power of Turkey, we will further our efforts towards a better world and a better future with our corporate citizen identity, industry-focused mission, social priorities, universal principles and conscious approach in the coming period.”
 
About CDP

CDP, an international not-for-profit organization established in 2000 in London where it is now headquartered, aims to change the ways of working of the business world in order to reduce the effects of climate change and protect natural resources. Through the CDP, which was initiated to collect and share information that would enable companies, investors and governments to take measures against the threat of climate change, around 8,000 organizations voluntarily disclose data on their greenhouse gas emissions, climate change strategies and sustainable water use to the public and investors. Boasting the world's largest corporate climate change, water and forest-risk data, CDP acts on behalf of 515 investors managing assets worth of US$ 106 trillion as of 2020 and calls on the world's leading companies to disclose their environmental policies. The organization has played an active role in the business world and policymaking processes in recent years not only with its main programs but also with the campaigns and environmental movements it leads around the globe.

A key advocate of sustainability action, Abdi İbrahim has pledged its support to global environment initiatives alongside its already-strong national and international contribution to the COVID-19 recovery efforts. Abdi İbrahim became the first Turkish signatory of the Recover Better statement, a joint effort by the Science Based Targets initiative and the UN, as one of the 155 companies that call for policies and action to continue the environmental recovery resulting from limited human movement during the pandemic and aim to maintain this positive impact in a sustainable manner in the future with support from businesses and organizations.

Abdi İbrahim, leading the industry on sustainability by always prioritizing efforts to leave a “better” mark on the society and world, became one of the signatories of the Recover Better statement, a joint initiative by the Science Based Targets initiative and the United Nations aiming to continue the positive impact of the climate action in the COVID-19 recovery process. Abdi İbrahim is the first Turkish company to become a signatory of the statement.

Part of the Science Based Targets initiative, Abdi İbrahim pledged its support for the Recover Better statement, urging governments around the world to align their COVID-19 economic aid and recovery efforts with the latest climate change. The Recover Better statement was signed by 155 companies with a combined market capitalization of over US$ 2.4 trillion and representing over 5 million employees. The statement calls governments to set and work towards science-based targets in their spending as part of economic recovery packages, accelerate the transition to a low-carbon economy, focus on the efforts to limit global warming to 1.5°C and integrate sustainability into all levels of public policymaking.

“The world is going through a challenging period due to the COVID-19 outbreak. Yet, the measures taken in response have started a significant environmental recovery due to limited human movement,” said Oğuzcan Bülbül, Director of Public Relations and Corporate Communications at Abdi İbrahim. “As such, it would be safe to say that this current situation, which has provided important lessons for governments, organizations and individuals, has a positive impact on climate change. In order to continue this recovery in the future, environment action must come from sustained, conscientious efforts rather than pandemics or other global disasters.”

“At Abdi İbrahim, we understand that we have an important role to play in the fight against climate change. The COVID-19 pandemic revealed the importance of sustainability once again, and we remain committed to integrate it into our business. Fully aware that human health directly linked with the health of our planet, we continue to take part in solutions that will improve our world and our future. For us, it is a matter of pride to become the first Turkish signatory of the Recover Better statement, which is a joint effort between Science Based Targets initiative and the UN. We hope to set an example in our industry.”

Recently, Abdi İbrahim took a significant step in its commitment to heal the future and the world by signing the UN Global Compact initiative CEO Water Mandate to support water policy and action on the global scale.

The company is also a signatory of the “Business Community Plastic Initiative”, a joint undertaking between Global Compact Turkey, Business World and Sustainable Development Association (SKD Turkey) and Turkish Industry and Business Association (TUSIAD). Abdi İbrahim has also set important targets in this context, such as becoming a member of leading global organizations advocating sustainability, such as CPD and RE100, and obtaining the “B Corp Certification” in the medium term.

In 2020, Abdi İbrahim transitioned to a 100% renewable energy supply in its production facilities, starting with its manufacturing processes. The company aims to expand the scope of renewable energy use gradually to its entire business from supply and logistics and raw material procurement to marketing and sales towards the end-consumer side to eliminate its carbon footprint by 2030.

 

 

 

Abdi İbrahim announces plans to use solar and wind energy in all of its facilities from January 1, 2020  onwards

Active for 109 years in the pharmaceutical industry with the goal of healing life, Abdi İbrahim continues to crown its accomplishments internationally in management and public relations projects. Abdi İbrahim has won two bronze awards by one of the most prestigious business award platforms in the world, the Stevie International Business Awards. 

As a company that has consecutively led the Turkish pharma industry for the last 19 years and has strengthened its global position by entering a strategic partnership with the Swiss biopharma company OM Pharma in September 2020, Abdi Ibrahim continues its success, both in the domestic and the international arena. This year, Abdi Ibrahim has been granted two bronze awards by the US-based Stevie International Business Awards.

The Stevie International Business Awards, which selects from a pool of applications made in different project categories by prominent international companies, has granted Abdi Ibrahim’s Chairman Nezih Barut a bronze award in the “Chairman of the Year” category. The judging committee chose the winners based on their leadership and their company’s success since 2019.

Among the accomplishments for which Nezih Barut was awarded a Stevie Award in the Chairman of the Year category were his proactive decisions with regards to the medication used for the treatment of COVID-19, his decision to quickly manufacture and donate to the Ministry of Health the medication that was available throughout the world and that was part of the initial treatment protocol, the investments made in biotechnology, an area that is gaining more prominence every year, as it helps treat diseases that are otherwise not treatable by medicinal chemistry, Abdi Ibrahim’s performance in sustainability and fight against climate change, as proven by being the first pharma company in Turkey to publicly announce its goal to go carbon neutral by 2030 in line with the Paris Climate Agreement, and the company’s 2020 investment in the Swiss biopharma company OM Pharma through a Swiss joint venture, which gave them 28.5% share ownership and led Abdi Ibrahim to become the first and only Turkish company to have a strategic partnership with a European company. In addition to his role as the Chairman of the Board at Abdi Ibrahim, Nezih Barut has also been serving as the Chairman of Pharmaceutical Manufacturers Association of Turkey (İEİS) for the last 13 years.

 Abdi Ibrahim’s “Viral Agenda”, a project through which much-needed current and evidence-based medical information is shared with the public during the pandemic, was given a bronze award in the “Communications/PR Campaign of the Year- COVID-19 Related Information (in the “COVID-19 Response” category). 

Award Winning Project “Viral Agenda” provides accurate information on COVID-19

Launched in 2002, the Stevie International Business Awards receive over 12 thousand applications from persons/companies/projects/campaigns in 8 categories and their sub-categories. This year, Abdi Ibrahim has received two awards after being evaluated by a committee composed of 260 industry professionals.

The Viral Agenda communication project, which won the bronze award in the Communications/PR Campaign of the Year category, was initiated to stop the spread of  misinformation and provide accurate information. The project involved scanning through hundreds of articles published around the world with the aim of providing updated and reliable information weekly on COVID-19, first to doctors and other health workers, and then to the general public, using simpler terms. The Viral Agenda was prepared by a group of doctors from different specialization fields, working under Abdi Ibrahim’s Medical Directorate, and it was communicated to the 4600 employees of the company and the target audience on a weekly basis through e-mail, LinkedIn, Twitter, Facebook and Instagram accounts. Through this project, the spread of unscientific or unverified information was stopped



For information: 

Hill + Knowlton Strategies – +90 212 270 52 32 

Burcu Yakar: Media Director- +90 532 779 30 18 / [email protected] 

Mustafa Salih: Media Director- +90 536 863 19 04 / [email protected]

 

 

Turkey’s leading pharma company, Abdi Ibrahim, has been given the manufacturing permit for COVID-19 vaccines, after proving its capacity to manufacture with the highest standards. Abdi Ibrahim’s Chairman of the Board of Directors, Nezih Barut, stated, “This permit, granted to us following the audits conducted by the Ministry of Health officials, proves that we are capable of manufacturing vaccines according to global standards”.

Conducting its activities in the Turkish pharmaceuticals industry for 109 years, and as the market leader for the last 19 years, Abdi Ibrahim has recently been given the permit to manufacture, fill and finish COVID-19 vaccines, a testament to its capacity to manufacture at the highest standards.

Chairman of the Board of Directors at Abdi Ibrahim, Nezih Barut, revealed that following the inspections and audits conducted by the Ministry of Health officials, Abdi Ibrahim was given the permit to manufacture mRNA-based and inactivated vaccines, and to perform the fill and finish process. He went on to say, “In December, we obtained the permit from the Ministry of Health to manufacture and to fill and finish both mRNA and inactivated vaccines for human use. For the manufacturing, as well as the fill and finish of vaccines, a sturdy infrastructure and an effective quality management system are necessary. This permit, given following the inspections conducted by the Ministry, once again certifies the competency of AbdiBio facility and our capacity to manufacture vaccines.”

After highlighting that Abdi Ibrahim has been offering its R&D and manufacturing power and its medical competencies, expertise and experiences to the service of Turkish medicine and patients in the fight against the pandemic, Nezih Barut continued with remarks on the manufacturing of the vaccine: “As a leader in our industry, we prioritized the needs of our nation and contributed to the fight with the best of our ability. While closely monitoring the global progress in vaccine development, we also applied to the Ministry of Health to obtain the permit to manufacture different varieties of the COVID-19 vaccine in the facilities at Abdi Ibrahim, Turkey’s national pharma company. Following the inspections, our AbdiBio facility obtained the permit to manufacture and to fill and finish both the mRNA-based biotechnical vaccines, manufactured by BioNTech and Moderna, and the inactivated vaccines manufactured by Russian and Chinese companies. This permit has proven that both our infrastructure and quality management systems are of high-quality.”

Emphasizing that Abdi Ibrahim has the necessary technology and infrastructure to manufacture and to fill and finish vaccines, Barut said “We have made considerable investments in biotechnology, an area to which we attribute great strategic importance and consider to be the future of pharmaceuticals. Our biotech medicine production facility, AbdiBio, completed in 2018, is the biggest step we have taken so far in this area. The goal of all the investments we make in biotechnology, including the manufacturing of vaccines, is to turn Turkey into a manufacturing center and a key player in this strategic area. Currently Abdi Ibrahim has the capacity to manufacture 20 million vaccines. If any additional investments are needed to manufacture more COVID-19 vaccines, we are ready to invest more in a short amount of time.”
 

For Information:

Hill + Knowlton Strategies +90 212 270 52 32 

Bülent Değerli: Media Director+90 545 233 24 28 / [email protected] 

Mustafa Salih: Media Director+90 536 863 19 04 / [email protected]

 

 

 

Abdi İbrahim, operating in the pharmaceuticals industry for the last 108 years, and the consecutive market leader in the last 18, took part in a Swiss joint venture that acquired OM Pharma, a 83-year pharma company based in Switzerland, one of the leading countries in Pharmaceutical Industry. The acquisition made Abdi İbrahim first and only Turkish  pharma company to form a strategic partnership with a European counterpart.

Abdi İbrahim, Turkey’s leading pharmaceutical company having built the largest biotechnological manufacturing facility of the country, entered a strategic partnership with the Icelandic pharmaceutical company Alvotech to manufacture and launch biotechnology drugs in Turkey.